🌐 Future Projection of Opioid Induced Constipation Oic Drugs Market ( )
The drug addresses a common side effect of opioid painkillers that decreases the gastrointestinal tract's motility. OIC drugs, such as
Methylnaltrexone has already been approved for the treatment of OIC in adults with chronic noncancer pain as well as for OIC in adults with
Opioid-induced constipation (OIC) is a common side effect of opioids. OIC. is a different type of constipation because it's caused by the activity of opioids in
by S Akhgarandouz 2024Opioid-induced constipation (OIC) is the most prevalent side effect of methadone maintenance therapy (MMT). Naloxone could reduce the OIC.
Prescribing a PAMORA to treat OIC adds to drug costs, but these costs may offset against the costs of treating OIC. To quantify costs associated with OIC, a retrospective study of adult data from 2024 to 2024 using Truven Health MarketScan Commercial and Medicare databases (n=13,808 nonelderly and 2,958 elderly patients) was conducted.
Results. Among 11,135 patients in the OIC-Rx cohort (21,474 in the No OIC-Rx cohort), 93% received methylnaltrexone SC. Patients in the OIC-Rx cohort had 0.7 fewer inpatient days per OIC ED encounter and 64% decreased odds of being hospitalized versus the No OIC-Rx cohort (both p 0.001).
background. Opioid-induced constipation (OIC) is a common and dominant adverse effect of opioid treatment. Current treatment standards of OIC advice general
Using PAMORAs to treat OIC. Peripheral-acting mu opioid receptor antagonists (PAMORAs) are drugs that act directly on the mechanism causing OIC
Comments